European Vaccine Initiative: lessons from developing malaria vaccines
2011 (English)In: Expert Review of Vaccines, ISSN 1476-0584, Vol. 10, no 12, 1697-1708 p.Article in journal (Refereed) Published
For over 10 years, the European Vaccine Initiative (EVI; European Malaria Vaccine Initiative until 2009) has contributed to the development of 24 malaria candidate vaccine antigens with 13 vaccine candidates being advanced into Phase I clinical trials, two of which have been transitioned for further clinical development in sub-Saharan Africa. Since its inception the EVI organization has operated as a funding agency, but with a clear service-oriented strategy. The scientific successes and difficulties encountered during these years and how these efforts have led to standardization and harmonization in vaccine development through large-scale European consortia are discussed. In the future, the EVI will remain instrumental in the pharmaceutical and clinical development of vaccines against ?diseases of poverty? with a continued focus on malaria. EVI will continue to focus on funding and managing preclinical evaluation up to Phase I/II clinical trials and strengthening the vaccine-development infrastructure in Europe, albeit with a global orientation.
Place, publisher, year, edition, pages
2011. Vol. 10, no 12, 1697-1708 p.
diseases of poverty; EMVI; EVI; malaria; PDP; research infrastructure; vaccine
IdentifiersURN: urn:nbn:se:su:diva-65711DOI: 10.1586/erv.11.158ISI: 000297804300014PubMedID: 22085173OAI: oai:DiVA.org:su-65711DiVA: diva2:464452